• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Switox:痉挛管理中肉毒杆菌毒素转换的回顾性分析。

Switox: Retrospective Analysis of Botulinum Toxin Switching in Management of Spasticity.

作者信息

Leblong Emilie, Piette Patrice, Anne Carole, Jeanne Maud, Poyau Marion, Roy Anne Laure, Gallien Philippe

机构信息

Fondation Saint Helier, 35043 Rennes, France.

出版信息

Toxins (Basel). 2025 Feb 24;17(3):103. doi: 10.3390/toxins17030103.

DOI:10.3390/toxins17030103
PMID:40137876
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11945378/
Abstract

This retrospective study investigates botulinum toxin changes in 206 patients with spasticity, following reimbursement adjustments in France. The main objective was to evaluate the tolerance and efficacy of these changes, a topic underexplored due to the common practice of maintaining the same toxin brand. The majority of patients switched from Botox to Xeomin (73.66%), while others switched from Botox to Dysport (14.63%) or from Xeomin to Dysport (11.71%). Dose adjustments varied depending on the switch, with the change from Botox to Xeomin showing the greatest diversity in adjustments. Overall, tolerance was good, with few adverse effects reported, primarily fatigue. Perceived efficacy fluctuated, with some patients noting improvement while others experienced deterioration, but the median remained stable. A majority of patients (57.06%) chose to continue with their new treatment, indicating general satisfaction, though 42.93% preferred to return to their initial treatment. This study highlights the importance of an individualized approach and careful monitoring during toxin changes. The results suggest that toxin switches can be made without an increase in adverse effects. While differences between groups were observed, they were not statistically significant. Placebo and nocebo effects may influence perceptions of efficacy and side effects during treatment changes.

摘要

这项回顾性研究调查了法国报销政策调整后206例痉挛患者肉毒杆菌毒素的变化情况。主要目的是评估这些变化的耐受性和疗效,由于通常维持使用同一毒素品牌的做法,该主题尚未得到充分探索。大多数患者从保妥适(Botox)换用了司库奇尤单抗(Xeomin)(73.66%),而其他患者从保妥适换用了丽舒妥(Dysport)(14.63%)或从司库奇尤单抗换用了丽舒妥(11.71%)。剂量调整因换药情况而异,从保妥适换用司库奇尤单抗时调整的多样性最大。总体而言,耐受性良好,报告的不良反应很少,主要是疲劳。感知到的疗效有所波动,一些患者注意到有所改善,而另一些患者则病情恶化,但中位数保持稳定。大多数患者(57.06%)选择继续接受新治疗,表明总体满意,不过42.93%的患者更愿意恢复初始治疗。这项研究强调了在毒素更换期间采取个体化方法和仔细监测的重要性。结果表明,更换毒素不会增加不良反应。虽然观察到组间存在差异,但无统计学意义。安慰剂和反安慰剂效应可能会影响治疗更换期间对疗效和副作用的认知。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47b1/11945378/4dd901c04b7e/toxins-17-00103-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47b1/11945378/4dd901c04b7e/toxins-17-00103-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47b1/11945378/4dd901c04b7e/toxins-17-00103-g001.jpg

相似文献

1
Switox: Retrospective Analysis of Botulinum Toxin Switching in Management of Spasticity.Switox:痉挛管理中肉毒杆菌毒素转换的回顾性分析。
Toxins (Basel). 2025 Feb 24;17(3):103. doi: 10.3390/toxins17030103.
2
[Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].[肉毒杆菌毒素治疗多发性硬化症患者的髋内收肌痉挛]
Wien Klin Wochenschr. 2001;113 Suppl 4:20-4.
3
Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions.从注射用肉毒毒素 A 转换为注射用阿替瑞林治疗神经疾病的剂量转换率、疗效比较和不良反应。
Clin Neurol Neurosurg. 2021 Oct;209:106889. doi: 10.1016/j.clineuro.2021.106889. Epub 2021 Aug 13.
4
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.临床实践中保妥适、吉适和乐提葆之间的换算比例。
Toxins (Basel). 2016 Mar 4;8(3):65. doi: 10.3390/toxins8030065.
5
A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke.一项关于A型肉毒杆菌毒素治疗中风患者上肢痉挛疗效和安全性的随机、双盲、安慰剂对照研究。
Eur J Neurol. 2001 Nov;8(6):559-65. doi: 10.1046/j.1468-1331.2001.00277.x.
6
A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke.一项随机、双盲、安慰剂对照、剂量范围研究,旨在比较三种剂量的A型肉毒杆菌毒素(Dysport)与安慰剂对中风后上肢痉挛的疗效和安全性。
Stroke. 2000 Oct;31(10):2402-6. doi: 10.1161/01.str.31.10.2402.
7
Safety profile of incobotulinum toxin A [Xeomin(®)] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial.A型肉毒杆菌毒素[Xeomin(®)]在脑瘫儿童腓肠肌注射中的安全性概况:随机双盲临床试验。
Eur J Paediatr Neurol. 2016 Jul;20(4):532-7. doi: 10.1016/j.ejpn.2016.04.008. Epub 2016 Apr 22.
8
Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.当经尿道内注射肉毒毒素 A 治疗失败时,改用阿博特毒素 A 可能对治疗神经原性逼尿肌过度活动有效。
Neurourol Urodyn. 2018 Jan;37(1):291-297. doi: 10.1002/nau.23291. Epub 2017 Apr 21.
9
Botulinum toxin treatment of adult spasticity : a benefit-risk assessment.肉毒杆菌毒素治疗成人痉挛:获益-风险评估
Drug Saf. 2006;29(1):31-48. doi: 10.2165/00002018-200629010-00003.
10
Safety and self-reported efficacy of botulinum toxin for adult spasticity in current clinical practice: a prospective observational study.在当前临床实践中,肉毒毒素治疗成人痉挛的安全性和自我报告疗效:一项前瞻性观察研究。
Clin Rehabil. 2012 Feb;26(2):174-9. doi: 10.1177/0269215511412799. Epub 2011 Sep 21.

本文引用的文献

1
Gait analysis patterns and rehabilitative interventions to improve gait in persons with hereditary spastic paraplegia: a systematic review and meta-analysis.遗传性痉挛性截瘫患者改善步态的步态分析模式及康复干预:一项系统评价与荟萃分析
Front Neurol. 2023 Sep 20;14:1256392. doi: 10.3389/fneur.2023.1256392. eCollection 2023.
2
Clinical presentation of patients with lower limb spasticity undergoing routine treatment with botulinum toxin: baseline findings from an international observational study.下肢痉挛接受常规肉毒毒素治疗的患者的临床表现:一项国际观察性研究的基线结果。
J Rehabil Med. 2023 Oct 5;55:jrm4257. doi: 10.2340/jrm.v55.4257.
3
Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study.
炎症性肠病患者非医疗用生物类似药转换后的临床疗效和反安慰剂效应:一项前瞻性观察研究。
Dig Liver Dis. 2024 Jan;56(1):35-42. doi: 10.1016/j.dld.2023.06.022. Epub 2023 Jul 5.
4
Guidance in botulinum neurotoxin injection for lower extremity spasticity: Sihler's staining technique.下肢痉挛性疾病中肉毒毒素注射治疗的指导:Sihler 染色技术。
Surg Radiol Anat. 2023 Aug;45(8):1055-1062. doi: 10.1007/s00276-023-03178-9. Epub 2023 Jun 9.
5
Botulinum toxin in the management of myalgia in temporomandibular disorders: are all injections equal?肉毒毒素治疗颞下颌关节紊乱症肌痛:所有注射都一样吗?
Br J Oral Maxillofac Surg. 2023 Jan;61(1):89-93. doi: 10.1016/j.bjoms.2022.11.279. Epub 2022 Nov 29.
6
Repeated botulinum treatment of rabbit masseter causes cumulative tissue damage.反复肉毒毒素治疗兔咬肌可导致累积性组织损伤。
Arch Oral Biol. 2022 Sep;141:105480. doi: 10.1016/j.archoralbio.2022.105480. Epub 2022 Jun 11.
7
Safety and efficacy of Botulinum toxin type A preparations in cerebral palsy - an evidence-based review.A型肉毒毒素制剂在脑瘫中的安全性和有效性——基于循证的综述。
Neurol Neurochir Pol. 2021;55(2):158-164. doi: 10.5603/PJNNS.a2021.0032. Epub 2021 Apr 16.
8
Context matters: the psychoneurobiological determinants of placebo, nocebo and context-related effects in physiotherapy.背景很重要:物理治疗中安慰剂、反安慰剂及背景相关效应的心理神经生物学决定因素
Arch Physiother. 2020 Jun 11;10:11. doi: 10.1186/s40945-020-00082-y. eCollection 2020.
9
Botulinum Toxin Type A for Upper Limb Spasticity in Poststroke Patients: A Meta-analysis of Randomized Controlled Trials.A型肉毒毒素治疗脑卒中后上肢痉挛:一项随机对照试验的荟萃分析。
J Stroke Cerebrovasc Dis. 2020 Jun;29(6):104682. doi: 10.1016/j.jstrokecerebrovasdis.2020.104682. Epub 2020 Apr 15.
10
Efficacy and Safety of Botulinum Toxin Type A for Limb Spasticity after Stroke: A Meta-Analysis of Randomized Controlled Trials.A型肉毒毒素治疗脑卒中后肢体痉挛的疗效和安全性:一项随机对照试验的荟萃分析。
Biomed Res Int. 2019 Apr 7;2019:8329306. doi: 10.1155/2019/8329306. eCollection 2019.